Thrivent Financial for Lutherans Sells 827 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Thrivent Financial for Lutherans reduced its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,988 shares of the company’s stock after selling 827 shares during the quarter. Thrivent Financial for Lutherans owned about 0.06% of Amphastar Pharmaceuticals worth $1,076,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Wealthfront Advisers LLC bought a new position in Amphastar Pharmaceuticals in the 4th quarter valued at $9,268,000. Tiemann Investment Advisors LLC bought a new stake in Amphastar Pharmaceuticals during the fourth quarter valued at $258,000. Amundi boosted its stake in Amphastar Pharmaceuticals by 193.0% during the fourth quarter. Amundi now owns 19,583 shares of the company’s stock valued at $717,000 after buying an additional 12,899 shares during the period. PNC Financial Services Group Inc. grew its position in Amphastar Pharmaceuticals by 90.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company’s stock worth $156,000 after buying an additional 1,992 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Amphastar Pharmaceuticals in the 4th quarter worth about $3,450,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analysts Set New Price Targets

Separately, Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Friday, March 21st.

Amphastar Pharmaceuticals Stock Up 2.0 %

AMPH opened at $28.99 on Tuesday. The business’s fifty day simple moving average is $30.94 and its 200 day simple moving average is $39.77. Amphastar Pharmaceuticals, Inc. has a 52 week low of $25.89 and a 52 week high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.38 billion, a PE ratio of 9.66, a P/E/G ratio of 2.19 and a beta of 0.77.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.